Cargando…

Correlates of late-onset antipsychotic treatment resistance

INTRODUCTION: There is emerging evidence of heterogeneity within treatment-resistance schizophrenia (TRS), with some people not responding to antipsychotic treatment from illness onset and a smaller group becoming treatment-resistant after an initial response period. It has been suggested that these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fonseca De Freitas, D., Agbedjro, D., Kadra-Scalzo, G., Francis, E., Ridler, I., Pritchard, M., Shetty, H., Segev, A., Casetta, C., Smart, S., Morris, A., Downs, J., Christensen, S., Bak, N., Kinon, B., Stahl, D., Hayes, R., Maccabe, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567017/ http://dx.doi.org/10.1192/j.eurpsy.2022.2018

Ejemplares similares

Clinical correlates of early onset antipsychotic treatment resistance
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

A predictor model of treatment resistance in schizophrenia using data from electronic health records
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality
por: Kadra, G., et al.
Publicado: (2018)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
por: Kadra, Giouliana, et al.
Publicado: (2015)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure
por: Downs, Johnny, et al.
Publicado: (2019)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Incidence of suicidality in people with depression over a 10-year period treated by a large UK mental health service provider
por: Francis, Emma R., et al.
Publicado: (2021)

Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration
por: Egerton, Alice, et al.
Publicado: (2022)

Defining severity of personality disorder using electronic health records: short report
por: Monk-Cunliffe, Jonathan, et al.
Publicado: (2023)

Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2021)

Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records
por: Downs, Johnny, et al.
Publicado: (2015)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM
por: Segev, Aviv, et al.
Publicado: (2021)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Ethnic inequities in multimorbidity among people with psychosis: a retrospective cohort study
por: Fonseca de Freitas, D., et al.
Publicado: (2022)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

Adverse outcomes associated with recorded victimization in mental health electronic records during the first UK COVID-19 lockdown
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource
por: Perera, Gayan, et al.
Publicado: (2016)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium
por: Smart, Sophie E., et al.
Publicado: (2022)

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
por: Liu-Seifert, Hong, et al.
Publicado: (2005)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir, Sibel, et al.
Publicado: (2016)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
por: Bak, Maarten, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8g0oudfntko1fe5hrpfeh1e4a8